Incidence of Concurrent Atrial Fibrillation in Patients Who Present with Atrial Tachycardia and Atrial Flutter Postablation for Persistent Atrial Fibrillation
Sergio Conti,Chen-yang Jiang,Timothy R. Betts,Jian Chen,Isabel Deisenhofer,Roberto Mantovan,Laurent Macle,Carlos A. Morillo,Wilhelm Haverkamp,Rukshen Weerasooriya,Jean-Paul Albenque,Stefano Nardi,Endrj Menardi,Paul Novak,Prashanthan Sanders,Atul Verma
DOI: https://doi.org/10.1161/circep.120.008683
2021-01-01
Circulation Arrhythmia and Electrophysiology
Abstract:HomeCirculation: Arrhythmia and ElectrophysiologyVol. 14, No. 3Incidence of Concurrent Atrial Fibrillation in Patients Who Present With Atrial Tachycardia and Atrial Flutter Postablation for Persistent Atrial Fibrillation Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBIncidence of Concurrent Atrial Fibrillation in Patients Who Present With Atrial Tachycardia and Atrial Flutter Postablation for Persistent Atrial FibrillationInsights From the STAR AF II Trial Sergio Conti, MD, Chen-yang Jiang, MD, Timothy R. Betts, MD, MB, ChB, Jian Chen, MD, Isabel Deisenhofer, MD, Roberto Mantovan, MD, PhD, Laurent Macle, MD, Carlos A. Morillo, MD, Wilhelm Haverkamp, MD, PhD, Rukshen Weerasooriya, MD, Jean-Paul Albenque, MD, Stefano Nardi, MD, Endrj Menardi, MD, Paul Novak, MD, Prashanthan Sanders, MB, BS, PhD and Atul Verma, MD Sergio ContiSergio Conti https://orcid.org/0000-0001-6683-6781 Department of Cardiology, Southlake Regional Health Centre, Newmarket, ON, Canada (S.C., A.V.). Department of Cardiology, University of Tor Vergata, Rome, Italy (S.C.). Search for more papers by this author , Chen-yang JiangChen-yang Jiang Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China (C.-y.J.). Search for more papers by this author , Timothy R. BettsTimothy R. Betts https://orcid.org/0000-0001-9063-9905 Department of Cardiology, Oxford University Hospitals, John Radcliffe Hospital, United Kingdom (T.R.B.). Search for more papers by this author , Jian ChenJian Chen https://orcid.org/0000-0003-3008-5706 Department of Cardiology, Haukeland University Hospital, University of Bergen, Norway (J.C.). Search for more papers by this author , Isabel DeisenhoferIsabel Deisenhofer https://orcid.org/0000-0001-5826-6846 Deutsches Herzzentrum München, Munich, Germany (I.D.). Search for more papers by this author , Roberto MantovanRoberto Mantovan https://orcid.org/0000-0002-9970-7924 Department of Cardiology, Ospedale S. Maria di Ca’ Foncelli, Treviso, Italy (R.M.). Search for more papers by this author , Laurent MacleLaurent Macle https://orcid.org/0000-0002-3328-5239 Montreal Heart Institute, QC, Canada (L.M.). Search for more papers by this author , Carlos A. MorilloCarlos A. Morillo https://orcid.org/0000-0002-8739-2099 Department of Cardiac Sciences, Libin Cardiovascular Institute, University of Calgary, AL, Canada (C.A.M.). Search for more papers by this author , Wilhelm HaverkampWilhelm Haverkamp https://orcid.org/0000-0002-6183-2519 Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany (W.H.). Search for more papers by this author , Rukshen WeerasooriyaRukshen Weerasooriya Department of Cardiology, Hollywood Private Hospital, Nedlands, Western Australia (R.W.). Department of Cardiology, University of Western Australia, Crawley (R.W.). Search for more papers by this author , Jean-Paul AlbenqueJean-Paul Albenque Département de Rythmologie, Clinique Pasteur Toulouse, France (J.-P.A.). Search for more papers by this author , Stefano NardiStefano Nardi https://orcid.org/0000-0001-6906-1766 Department of Cardiology, Pineta Grande Hospital, Castel Volturno, Italy (S.N.). Search for more papers by this author , Endrj MenardiEndrj Menardi https://orcid.org/0000-0003-2184-3093 Department of Cardiology, Ospedale Santa Croce e Carle, Cuneo, Italy (E.M.). Search for more papers by this author , Paul NovakPaul Novak Department of Cardiology, Royal Jubilee Hospital, Victoria, BC, Canada (P.N.). Search for more papers by this author , Prashanthan SandersPrashanthan Sanders https://orcid.org/0000-0003-3803-8429 Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Australia (P.S.). Search for more papers by this author and Atul VermaAtul Verma Correspondence to: Atul Verma, MD, 602-581 Davis Dr, Newmarket, ON, Canada, L3Y 2P6. Email E-mail Address: [email protected] https://orcid.org/0000-0002-1020-9727 Department of Cardiology, Southlake Regional Health Centre, Newmarket, ON, Canada (S.C., A.V.). Department of Cardiology, University of Toronto, ON, Canada (A.V.). Search for more papers by this author Originally published4 Mar 2021https://doi.org/10.1161/CIRCEP.120.008683Circulation: Arrhythmia and Electrophysiology. 2021;14:e008683Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: March 4, 2021: Ahead of Print The pattern of recurrence of atrial fibrillation (AF), atrial tachycardia (AT), and atrial flutter (AFL) post-AF ablation is not well known. Postablation, patients who present with predominantly AT/AFL will often undergo focused reablations where those specific ATs/AFLs are targeted. However, with more frequent monitoring, concomitant AF may also be found in these patients, which may have implications for the redo strategy. The STAR AF II (Substrate and Trigger Ablation for Reduction of Atrial Fibrillation 2) was a large prospective, multicenter, randomized trial comparing different approaches to persistent AF ablation.1 The trial employed a rigorous monitoring strategy including Holters and transtelephonic monitoring to assess for arrhythmia recurrence postablation. Given the abundance of patients and monitoring in the trial, we evaluated the incidence of purely isolated AT/AFL recurrence and the incidence of concomitant AF in patients who presented with predominantly AT/AFL recurrences after ablation of persistent AF. The study was approved by an institutional review committee and that the subjects gave informed consent.In STAR AF II, patients were randomized to pulmonary vein isolation alone, pulmonary vein isolation plus complex fractionated atrial electrograms ablation, and pulmonary vein isolation plus linear ablation. Patients were followed for 18 months with a visit, ECG, and 24-hour Holter at 3, 6, 9, 12, and 18 months, plus weekly and symptoms-driven transtelephonic monitoring. After the blanking period, recurrence was defined as any documented atrial arrhythmia >30 s after one procedure on or off antiarrhythmics. All documented recurrences were classified either as AF or AFL/AT by the core lab in the original trial. In the current analysis, patients were divided into different groups according to the type of arrhythmia documented during the blanking period and follow-up: recurrence of AT/AFL only; recurrence of AF only; recurrence of both AT/AFL and AF but with more than half of the episodes classified as AT/AFL; and recurrence of both AT/AFL and AF with more than half the episodes classified as AF.The data that support the findings of this study are available from the corresponding author upon reasonable request.Five hundred forty-nine patients underwent ablation and completed the 18-month follow-up. Compliance for all visits was 90%, for Holter was 85%, and for transtelephonic monitoring was 75%. Among the patients who had any arrhythmia recurrence (312/549 patients), 14.7% had recurrence of AT/AFL only, 30.8% had recurrence of AF only, and 54.5% had recurrence of both AF and AT/AFL. When the recurrence pattern during the blanking period was compared with the recurrence pattern during follow-up, among patients who had only AT/AFL recurrences, 44.5% had recurrence of AT/AFL only, 11.1% had AF only, 44.4% had both AT/AFL and AF; in patients with recurrence of AF only, 5.3% had recurrence of AT/AFL only, 42.7% had AF only, and 52.0% had both AF and AT/AFL recurrences. Among patients with recurrence of both AF and AT/AFL during the blanking period with more than half of episodes being AT/AFL, 15.5% had recurrence of AT/AFL only, 6.7% had AF only, 77.8% had both AF and AT/AFL. Among patients with recurrence of both AF and AT/AFL with more than half episodes being AF, 3.6% had recurrence of AT/AFL only, 21.8% had AF only, 74.6% had both AF and AT/AFL episodes. Finally, among patients who did not have any recurrence during the blanking period, 22% had recurrence of AT/AFL only, 29% had AF only, 49% had both AF and AT/AFL recurrences (Table).Table. Analysis of Recurrence Pattern During Blanking Period and During Follow-UpRecurrence pattern during blanking periodRecurrence pattern during follow-upAT/AFL onlyAF onlyAT/AFL and AF (>50% AT/AFL)AT/AFL and AF (>50% AF)AT/AFL only44.5%11.1%33.3%11.1%AF only5.3%42.7%9.3%42.7%AT/AFL and AF15.5%6.7%51.1%26.7%AF indicates atrial fibrillation; AFL, atrial flutter; and AT, atrial tachycardia.In this substudy, we demonstrate that only a minority of patients (14.7%) present solely with AT/AFL as their arrhythmia recurrence. The majority of patients present with both AT/AFL and AF. In those patients who present predominantly with AT/AFL, about a quarter of the recurrences are still AF. Finally, when the blanking period recurrence pattern is compared to the pattern in long-term follow-up, more than half of patients who present initially with only AT/AFL will go on to develop AF. AT/AFL recurrence is known to occur in 8% to 40% of patients after AF ablation and can often be more rapid and symptomatic than the initial AF preablation.2,3 These arrhythmias frequently occur due to incomplete isolation or linear ablation performed during the initial ablation. It has been speculated if a focused approach for reablations targeting the specific AT/AFL should be adopted. However, given the frequency of AF recurrence reported in such patients in this substudy, this strategy should be questioned. Bai et al4 showed that for patients presenting with mitral dependent flutter post-AF ablation, reisolation of the pulmonary venous antra was more effective than ablating along the mitral isthmus. Our data showing the frequency of AF recurrence would support such data. This is consistent with the fact that pulmonary vein reconnection is seen in 30% to 90% of patients at the time of repeat ablation.5 Our findings must be taken into consideration when planning the optimal strategy of a reablation.By analyzing data from the large STAR AF II trial, we found that the recurrence rate of isolated AT/AFL is low compared with the recurrence rate of isolated AF or the combination of both AT/AFL and AF. Even among patients who experienced higher incidence of AT/AFL recurrences, AF was roughly present in about a quarter of all recorded episodes.Nonstandard Abbreviations and AcronymsAFatrial fibrillationAFLatrial flutterATatrial tachycardiaSTAR AF IISubstrate and Trigger Ablation for Reduction of Atrial Fibrillation 2Sources of FundingNone.Disclosures Dr Betts has received research funding from St. Jude Medical. Dr Macle has received lecture fees and research funding from St. Jude Medical and Biosense Webster. Dr Morillo has received honoraria from St. Jude Medical, grants from BSCI, and is a member of the Advisory Board for Bayer. Dr Albenque has been a consultant to St. Jude Medical and Biosense Webster. Dr Sanders has served on the Advisory Boards of Biosense Webster, Medtronic, St. Jude Medical, Boston Scientific, and CathRx; has received lecture and/or consulting fees from Biosense Webster, Medtronic, St. Jude Medical, and Boston Scientific; and has received research funding from Medtronic, St. Jude Medical, Boston Scientific, Biotronik, and Sorin. Dr Verma has received grants from Biosense Webster, Medtronic, Bayer, and Boehringer Ingelheim and is a member of the Advisory Boards for Biosense Webster and Bayer. Dr Sanders is supported by a Practitioner Fellowships from the National Health and Medical Research Council of Australia and by the National Heart Foundation of Australia. The other authors report no conflicts.FootnotesFor Sources of Funding and Disclosures, see page 366.Correspondence to: Atul Verma, MD, 602-581 Davis Dr, Newmarket, ON, Canada, L3Y 2P6. Email atul.[email protected]caReferences1. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, et al.; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation.N Engl J Med. 2015; 372:1812–1822. doi: 10.1056/NEJMoa1408288CrossrefMedlineGoogle Scholar2. Chugh A, Oral H, Lemola K, Hall B, Cheung P, Good E, Tamirisa K, Han J, Bogun F, Pelosi F, et al.. Prevalence, mechanisms, and clinical significance of macroreentrant atrial tachycardia during and following left atrial ablation for atrial fibrillation.Heart Rhythm. 2005; 2:464–471. doi: 10.1016/j.hrthm.2005.01.027CrossrefMedlineGoogle Scholar3. Rostock T, Drewitz I, Steven D, Hoffmann BA, Salukhe TV, Bock K, Servatius H, Aydin MA, Meinertz T, Willems S. Characterization, mapping, and catheter ablation of recurrent atrial tachycardias after stepwise ablation of long-lasting persistent atrial fibrillation.Circ Arrhythm Electrophysiol. 2010; 3:160–169. doi: 10.1161/CIRCEP.109.899021LinkGoogle Scholar4. Bai R, Di Biase L, Mohanty P, Dello Russo A, Casella M, Pelargonio G, Themistoclakis S, Mohanty S, Elayi CS, Sanchez J, et al.. Ablation of perimitral flutter following catheter ablation of atrial fibrillation: impact on outcomes from a randomized study (PROPOSE).J Cardiovasc Electrophysiol. 2012; 23:137–144. doi: 10.1111/j.1540-8167.2011.02182.xCrossrefMedlineGoogle Scholar5. Lin D, Santangeli P, Zado ES, Bala R, Hutchinson MD, Riley MP, Frankel DS, Garcia F, Dixit S, Callans DJ, et al.. Electrophysiologic findings and long-term outcomes in patients undergoing third or more catheter ablation procedures for atrial fibrillation.J Cardiovasc Electrophysiol. 2015; 26:371–377. doi: 10.1111/jce.12603CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails March 2021Vol 14, Issue 3 Advertisement Article InformationMetrics © 2021 American Heart Association, Inc.https://doi.org/10.1161/CIRCEP.120.008683PMID: 33657834 Originally publishedMarch 4, 2021 Keywordspulmonary veinatrial fibrillationtachycardiarecurrenceatrial flutterPDF download Advertisement SubjectsAtrial Fibrillation